| | |
| Clinical data | |
|---|---|
| Trade names | Partruvix |
| Other names | BGB-290 |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C16H15FN4O |
| Molar mass | 298.321 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Pamiparib, sold under the brand name Partruvix, is a pharmaceutical drug used for the treatment of various types of cancer. Pamiparib is a member of the PARP inhibitor drug class. [1]
In China, it is approved for the treatment of germline BRCA mutation-associated recurrent advanced ovarian, fallopian tube, and primary peritoneal cancers previously treated with two or more lines of chemotherapy. [2]
It is currently under investigation for the treatment of other forms of cancer. [3] [1]